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Abstract
Background: Current outbreaks of COVID-19 are threatening the health care systems of several countries around
the world. Control measures, based on isolation, contact tracing, and quarantine, can decrease and delay the
burden of the ongoing epidemic. With respect to the ongoing COVID-19 epidemic, recent modeling work shows
that these interventions may be inadequate to control local outbreaks, even when perfect isolation is assumed. The
effect of infectiousness prior to symptom onset combined with asymptomatic infectees further complicates the use
of contact tracing. We aim to study whether antivirals, which decrease the viral load and reduce infectiousness,
could be integrated into control measures in order to augment the feasibility of controlling the epidemic.
Methods: Using a simulation-based model of viral transmission, we tested the efficacy of different intervention
measures to control local COVID-19 outbreaks. For individuals that were identified through contact tracing, we
evaluate two procedures: monitoring individuals for symptoms onset and testing of individuals. Additionally, we
investigate the implementation of an antiviral compound combined with the contact tracing process.
Results: For an infectious disease in which asymptomatic and presymptomatic infections are plausible, an
intervention measure based on contact tracing performs better when combined with testing instead of monitoring,
provided that the test is able to detect infections during the incubation period. Antiviral drugs, in combination with
contact tracing, quarantine, and isolation, result in a significant decrease of the final size and the peak incidence,
and increase the probability that the outbreak will fade out.
Conclusion: In all tested scenarios, the model highlights the benefits of control measures based on the testing of
traced individuals. In addition, the administration of an antiviral drug, together with quarantine, isolation, and
contact tracing, is shown to decrease the spread of the epidemic. This control measure could be an effective
strategy to control local and re-emerging outbreaks of COVID-19.
Background
The use of invasive non-pharmaceutical interventions
(i.e. full city lockdown (Wuhan), school closures, cutting
inter-city travel and intra-city mobility) was able to bring
the epidemic under control in China [1, 2], but these
measures are associated with profound societal and
economic disruptions. We investigate the use of contact
tracing and isolation in combination with an antiviral
compound to control local outbreaks of COVID-19, to
avoid such invasive social measures, and to preemptively
reduce the burden of the epidemic. Even when perfect
isolation is in place, this may not be sufficient to contain
a local COVID-19 outbreak [3], due to presymptomatic
transmission [4, 5]. Therefore, in the absence of a vac-
cine, an antiviral drug in addition to isolation could be
used to contain the current COVID-19 epidemic. There
are currently no potent and selective antivirals available
against coronaviruses. The development of such potent
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and safe drugs typically takes 10 years or longer. How-
ever, there are a number of drugs that either directly tar-
get a viral enzyme (such as the viral RNA-dependent
RNA polymerase, e.g., remdesivir and favipiravir) or that
have been developed for non-viral indications, but that
exert at least some level of antiviral activity (the so-
called repurposed drugs). We here assume that an anti-
viral drug will reduce the viral load of an infected indi-
vidual with COVID-19. For our modeling experiments,
we considered the experimental drug remdesivir, for
which viral load data were available to inform our
model. Remdesivir is an investigational, broad-spectrum
antiviral agent that was developed for the treatment of
Ebola virus infections. It is a nucleotide analog that in-
hibits the viral RNA-dependent RNA polymerase and
has activity against a wide range of RNA viruses [6]. It is
also active against SARS-CoV and MERS-CoV, which
can be explained by similarities in the active site of the
polymerase of these viruses. Based on this promising ac-
tivity against other coronaviruses, remdesivir was re-
cently shown to also inhibit SARS-CoV-2 in vitro [7]. As
a consequence, this drug is currently under evaluation
against COVID-19 in various clinical trials, and based on
preliminary efficacy data, the drug was granted emer-
gency use designation for severe COVID-19 patients by
the FDA on 1 May 2020. For the aforementioned rea-
sons, we chose to inform our model with data on the
control of MERS-CoV viral load by remdesivir in a
translational murine model [8]. This animal model was
specifically developed to better approximate the pharma-
cokinetics and drug exposure profile in humans. There-
fore, the measure of viral titers in lung tissue at different
time points in this murine model serves as a reasonable
proxy for viral dynamics upon compound exposure in
the controlled setting of a viral challenge. To this end,
we calibrate the model to represent the viral load de-
crease thereof.
In this manuscript, we first present the effect of isolation,
considering both home quarantine (for individuals that are
part of a contact trace network and for infected individuals
with mild symptoms) and hospital isolation (for severe
cases). We argue that when an individual is quarantined at
home, this will only result in a partial reduction of contacts,
since contacts with household members remain and other
breaks of isolation can occur. To compensate for this im-
perfect isolation, we consider the use of an antiviral com-
pound. We test these different control measures in a
simulation study that aims at representing, given the avail-
able information, the current COVID-19 epidemic. Many
countries are already beyond the point where local contain-
ment alone will suffice. However, we do expect that the
methodology we propose will be key to avoid a second
peak, especially given the limited depletion of susceptibles.
Methods
Epidemiological dynamics
The disease dynamics are depicted in the left panel of
Fig. 1. The possible transitions between epidemic classes
are described by the arrows.
Individuals are initially susceptible (S), and once in-
fected, they enter the exposed class (E). The infection
can be asymptomatic (Ia) if individuals do not show
symptoms during their infectious periods or symptom-
atic. Symptomatic individuals, after a presymptomatic
period (Ip), can show mild (Im) or severe symptoms (Is).
When diagnosed, symptomatic individuals are hospital-
ized (H) or are confined in home quarantine (Q), based
on the severity of symptoms. We assumed that hospital-
ized individuals are immediately isolated. Asymptomatic
individuals, however, are assumed to not be diagnosed.
Ultimately, all infectives are assumed to either recover
from infection or die (R). Isolation and quarantine start
at the time of diagnosis. Isolation is assumed to be per-
fect; therefore, individuals can no longer transmit the
disease. The quarantined individuals, instead, can still
make contacts, although at a decreased rate.
Transmission model
The transition from the susceptible to the exposed class
is governed by a stochastic process based on the notion
of infectious contact processes [9]. First, contacts be-
tween individuals are generated. When such contacts are
generated between susceptible and infectious people,
these can result in an infection event according to a Ber-
noulli experiment, using a probability value based on the
time since infection. This probability is computed, at a
precise time point, as the product of two components:
the infectiousness measure, υ(t), which quantifies the
level of infectiousness over time, and the total amount of
infectivity q, i.e., the number of expected effective con-
tacts over the contact rate [10]. The function υ(t) is de-
fined over the exposed and infectious period, or
analogously over the incubation and symptomatic
period, along which it integrates to one. This function is
scaled to have a similar shape among different infectives,
Fig. 1 Disease dynamics. Possible transitions among the different
epidemic compartments
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based on their lengths of exposed and infectious period.
According to this framework, an infectious individual
makes effective contacts at a rate, r(t), given by:
r tð Þ ¼ λ q  υ tð Þ; ð1Þ
where λ is the contact rate. The mean number of ef-
fective contacts is an approximation of the basic
reproduction number. The two quantities are identical
in an infinite and homogeneous population, where the
probability that an individual makes two effective con-
tacts with the same person is zero. For the considered
population size, the likelihood that this event occurs is
extremely low. Therefore, throughout the manuscript,
we approximate the basic reproduction number with the
mean number of effective contacts.
In this framework, isolation and quarantine are imple-
mented by reducing the contact rate λ. The infectiousness
measure υ(t) is set to represent the shape of the viral load
curve according to the assumption that higher viral load
corresponds to higher transmission probability.
Simulation parameters and distributions
In Table 1, we report the parameters and distributions
that were utilized in the simulation study. Where distri-
butions are not reported, the parameters are assumed to
be constant. In the last column, we report the literature
references that justify our choice of parameter value—or
distribution—we used.
We assume that symptomatic individuals make, on
average, between two and three effective contacts. This
value is set accordingly to the current estimate of the
basic reproduction number [11, 12, 15, 16]. The infec-
tiousness measure is set to represent the viral load ob-
servations reported in [13, 21, 22], the peak of which is
reached within a few days after symptom onset. Based
on the currently available information, we assume the
same viral load shape between mild, severe, and asymp-
tomatic individuals. The total length is informed using
the observations of symptomatic cases reported in Zou
et al. [13], and it is computed as the convolution of incu-
bation and symptomatic period. Asymptomatic individ-
uals are assumed to have lower transmission compared
to symptomatic ones. We set the asymptomatic
reproduction number, Ra0 , to be equal to 0.55 R
s
0. This
value was selected from the estimation presented in Li
et al. [17] for unreported cases. The proportion of
asymptomatic individuals is set to be equal to 31% [18].
The time to diagnosis is assumed to coincide with the
time of hospitalization. We set this value in line with the
estimation reported in Donnelly et al. [14] for SARS.
The chosen value is in line with recent estimation of the
time to hospitalization for COVID-19 reported in Linton
et al. [23]. At the time of diagnosis, symptomatic individ-
uals, depending on the severity of the symptoms, are iso-
lated (severe cases) or quarantined (mild cases). The
population size is set to 1000 to represent a localized
outbreak of COVID-19. We assume the population to be
homogeneous, closed, and finite. These assumptions re-
late to the control measures currently in place, which
aim at containing immigration to and emigration from a
country with an ongoing outbreak.
Contact tracing and isolation
In order to implement contact tracing, we keep track of
a contact history H i for each individual i, for all con-
tacts made since the time of infection. When an individ-
ual i is found to be infected with SARS-CoV-2, a contact
tracing procedure is started. We assume that each con-
tact in H i will be traced back successfully with prob-
ability η. Depending on the considered scenario, traced
back individuals will be monitored or tested, using a
PCR test. When individuals are found positive for SARS-
Table 1 Model parameters
Name Mean value (SD) Distribution Reference
Incubation period 5.2 days (2.8 days) Weibull [11, 12]
Symptomatic period length 18 days Exponential [13]
Time to diagnosis 3.8 days (2.45 days) Gamma [14]
Basic reproduction number
Symptomatic R s0 2.5 NA [11, 12, 15, 16]
Asymptomatic Ra0 1.375 NA [17]
Symptomatic Individuals 69% NA [18]
Severe cases 16% NA [19]
Population size 1000 NA Motivated in the text
Daily contact rate 12 contacts NA [20]
Infectiousness measure 10 days (3.8 days) Gamma [13, 21, 22]
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CoV-2, they will be put in quarantine/isolation. For cer-
tain scenarios, next to quarantine, we also inject infected
individuals with an antiviral drug (i.e., remdesivir).
We assume that the PCR test can detect infection after
2 days since infection. Traced individuals who test nega-
tive the first time are tested again after 2 days. The quar-
antine will result in a decreased contact rate (i.e.,
imperfect isolation), λq, while in case of perfect isolation
the contact rate is set to zero. Similarly, diagnosed indi-
viduals will also be quarantined: at home (mild symp-
toms), with a decreased contact rate λq, or in the
hospital (severe symptoms), where we assume that per-
fect isolation is possible. In all the considered scenarios,
16% of individuals are isolated while the rest are placed
in quarantine. The selected proportion reflects the pro-
portion of severe cases reported in Guan et al. [19]
Antiviral compounds
To compensate for imperfect isolation, we investigate
the use of antiviral compounds to reduce the infectious-
ness of an infected individual. Following earlier work
[24], we assume that once the antiviral compound has
been administered, the infectiousness measure will expo-
nentially decay according to an inverse Malthusian growth
model (shown in Fig. 2) [25]. The rate of this decay is set
to represent the reduction in viral load, due to remdesevir,
as reported in [8] for the MERS coronavirus.
Scenarios
We assume the following parameters for the reduction
of contacts because of home quarantine: λq = 0.1λ, 0.25λ,
0.5λ and for the probability of tracing back a contact in
history H i: η = 0.25, 0.5, 0.75 [26].
In all the considered scenarios, we assume that indi-
viduals are isolated, or quarantined, when diagnosed.
Moreover, we assume that contact tracing starts at the
time of diagnosis.
 IAS. Traced individuals are monitored for 2 weeks
and isolated/quarantined if they show symptoms
during this period. This scenario is similar to the
baseline scenario described by Hellewell et al. [3]
with the exception that in our description only
severe cases are isolated while the mild cases are
home quarantined. In addition, we include a
proportion of asymptomatic individuals that are not
detected. This scenario better reflects the current
practice of containment.
 IBS. Traced individuals are isolated/quarantined, as
soon as they test positive for SARS-COV-2. We as-
sume that the PCR test can detect a positive individ-
ual 2 days after infection. Therefore, a traced
individual is tested immediately when traced, and if
this test was negative, we test the individual again
2 days later.
 IBTBS. A diagnosed patient is immediately treated
with the antiviral drug. Furthermore, traced
individuals are isolated/quarantined and injected
with the antiviral drug, as soon as they test positive
for SARS-COV-2. We assume that the PCR test can
detect a positive individual 2 days after infection.
Therefore, a traced individual is tested immediately
when traced, and if this test was negative, we test
the individual again 2 days later.
For each scenario, we run 5000 simulations. Among
these, we compute the final size and the cases at peak
for the one in which at least the 10% of individuals have
Fig. 2 Reduction of infectiousness. The blue and the orange lines describe the infectiousness measure, respectively, before (dashed blue) and
after (solid yellow) antiviral administration. The red arrows indicate the start of the antiviral treatment (i.e., remdesivir)
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been infected. Doing this, we only account for outbreaks
that are most challenging to contain.
Results
Quarantine, isolation, and antiviral treatments lead, in
different levels, to the mitigation of the outbreak by re-
ducing the final size as well as by reducing the number
of cases at the peak of the epidemic. A control measure
based on monitoring is less effective in containing the
epidemic, even when a high proportion of contacts are
successfully traced. Instead, when a test is performed on
the traced individuals, the mitigation efficacy increases
depending on the probability of successfully traced con-
tacts (Figs. 3 and 4) since asymptomatic individuals are
possibly detected and the traced individuals who test
positive are immediately quarantined or isolated limiting
presymptomatic and asymptomatic infections. Isolation
and quarantine are therefore more effective when per-
formed prior to symptom onset, which is important, as
recent work shows that infectees are infectious prior to
symptom onset [5].
In terms of the magnitude among intervention strat-
egies, the antiviral treatment is shown to have the larger
impact and, together with quarantine and isolation, signifi-
cantly reduces the final size, the peak incidence, and the
number of outbreaks that are most challenging to contain.
Discussion
In this modeling study, a number of assumptions were
made, which we here discuss.
We assume an exponential decay model for the infec-
tiousness when the antiviral compound is administered.
To challenge this assumption, we perform a sensitivity
analysis where we consider a logistic curve (i.e., the
Gompertz model [27]: another common way to model
biological population processes) and a linear function
(Additional File 1: Fig. S1). This sensitivity analysis
shows that the different decay models yield similar re-
sults, supporting the robustness of our proposed preven-
tion scheme (Additional File 1: Fig. S2).
Regarding transmissibility, we tested the effect of a
longer mean incubation period of 6.4 days [28], while
keeping the infectiousness measure profile fixed. Doing
so, we investigated a higher probability of presymptom-
atic infections. Results reported in Additional File 1: Fig.
S6 indicate similar performance of the control strategies
based on testing, while monitoring is shown to be less
effective. Since SARS-CoV-2 also spreads in the pre-
symptomatic stage, testing and administering antivirals
are expected to be beneficial to reduce the number of
infectives.
In our baseline scenario, we assume that infected indi-
viduals can be identified using PCR testing starting
2 days post-infection. Furthermore, we investigated the
effect of a test that can only detect infection after 3 and
4 days since infection (Additional File 1: Fig. S11 and
Fig. S12). As expected, the efficacy of a control measure
based on testing is sensitive to detection timeframes, but
the control measure that uses antiviral drugs is still the
most effective among the ones that were tested.
Fig. 3 Final size distribution. Distributions of the final size value for scenario IAS (yellow), scenario IBS (green), and scenario IBTBS (blue) when the
quarantine contact rate is λq = 0.25λ together with the probability that a simulation leads to a number of cases smaller than the 10% of the
population (purple asterisks)
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Nevertheless, it is important to note that early diagnosis
seems feasible based on this recent work [29], where in-
dividuals in a nursing facility were found positive
through PCR test, prior to symptom onset. This indi-
cates that it is possible to diagnose patients early after
infection. Another recently published paper [4] states
that infectious coronavirus particles are shed at high
concentrations from the nasal cavity before symptom de-
velopment, which again indicates that it could be pos-
sible to detect infection early by means of PCR test.
We assume that we have sufficient antiviral drug doses
to treat all individuals that are encountered via the con-
tact tracing procedure and enough tests to detect their
infectious status. This is motivated by the fact that we
consider an emerging outbreak and the required number
of doses and tests will thus be limited.
Furthermore, in the baseline scenario, we assume that
all symptomatic individuals are in fact diagnosed. Due to
the awareness of COVID-19 given by media and govern-
ment officials, individuals are more likely to act upon
even mild symptoms. This assumption is in line with the
work of Hellewell et al. [3]. While this is a limitation of
our study, we argue that in the scenarios where we ag-
gressively trace and treat the contacts of individuals, we
are more likely to detect (and constrain) cases that
would otherwise go undetected. In addition, we investi-
gated the impact of a proportion of mild symptomatic
individuals that are not being diagnosed, unless they are
traced (Additional File 1: Fig. S3, Fig. S4, and Fig. S5).
As expected, all the tested control measures perform
better when a high percentage of individuals are
diagnosed. However, the use of antivirals in combination
with testing and isolation/quarantine remarkably reduces
the total number of cases and the peak incidence also in
these scenarios.
When severe cases are diagnosed or test positive, we
assume they are immediately placed in perfect isolation,
meaning that these infected individuals can no longer
transmit the infection. While this assumption is consist-
ent with earlier work [3], health care workers are still at
risk as they could be infected by infected individuals be-
ing cared for in isolation.
In the IBS and IBTBS scenarios, we assume that the
traced individuals that test positive are isolated in 16% of
cases, even before showing actual severe symptoms.
Although this model is informed with data on the con-
trol of MERS-CoV viral load using prophylaxis with
remdesivir, it stands to reason that different classes of
viral inhibitors control the viral load in different ways.
Additionally, despite the sequence similarity of MERS-
CoV and SARS-COV-2, it remains to be established
whether the impact of remdesivir (or other antivirals) on
the viral load is similar. Recently, clinical trials address-
ing the use of remdesivir in the treatment of SARS-
CoV-2 patients in different phases of their disease course
were initiated. The clinical outcomes of such antiviral
administrations are starting to be published in literature,
where the starting time of the treatment seems to be
crucial [30, 31]. Wang et al. reported a randomized trial
in which no statistically significant benefit was associated
with remdesivir [31]. However, it has been argued that
this trial is underpowered and therefore results in
Fig. 4 Peak incidence. Mean peak incidence value for scenario IAS (yellow), scenario IBS (green), and scenario IBTBS (blue) together with the 2.5%
and the 97.5% percentiles
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inconclusive findings [32]. In addition, in that trial, the
median time before the start of treatment was 10 days
from the start of disease onset, possibly reflecting a
phase in which the efficacy of antiviral administration is
more limited. In this phase, not only the viral presence
but also an excessive inflammatory response is a major
cause of patient death [33, 34]. Moreover, a more posi-
tive statement on the efficacy of remdesivir was recently
released, in which a moderate clinical improvement in
recovery time was reported in an additional clinical trial
(NCT04292899) [35].
However, the relationship between the effect of the
antiviral on the viral load is not available yet, especially
if administered in the early stage of the infection. To this
end, longitudinal data of the viral load on COVID-19 in-
fected patients treated with different viral inhibitors will
be informative, especially when the administration is
performed in the early stage of infection. Furthermore,
Sheahan et al. [8] demonstrated that the efficacy of
remdesivir for MERS depends on the viral dose and also
on the timing of the treatment of the viral inhibitor.
When mice were inoculated with a high inoculum of
virus, delayed start of antiviral treatment failed to fully
prevent viral pathogenesis. Although remdesivir proved
effective at reducing the viral load also under these con-
ditions, the argument for an early start of antiviral treat-
ment is evident. Presumably, reducing the viral load with
an antiviral compound loses its efficacy in advanced dis-
ease as the tissue damage is sustained by inflammatory
processes in absence of the viral initiator. We here suggest
to consider the proposed scenario based on remdesivir. In
our implementation, antiviral injections are immediately
administered to successfully traced individuals, mostly in
their asymptomatic phase, and to the diagnosed patient.
Therefore, we believe that the assumptions on the use of
this drug, in the considered scenario, are reasonable. Fur-
thermore, as remdesivir is a repurposed drug that was de-
veloped for Ebola, it remains possible that more potent
coronavirus inhibitors will be developed in the future.
We considered a homogeneous population that lacks
structured contact patterns. In fact, the probability of
successfully tracing contacts depends on the mixing be-
havior of the specific individual. In particular, close con-
tacts within the household are likely to be traced as well
as contacts in working places, school, and leisure envi-
ronments [36]. Since the majority of close contacts occur
in these locations, it is reasonable to assume that a high
proportion of secondary infections can be correctly
traced. Therefore, this analysis should be further investi-
gated in a more fine-grained individual based model
prior to moving this strategy to public health practice.
While a limited number of countries (Singapore, Hong
Kong, South Korea) were able to control the epidemic
through contact tracing without the use of an antiviral
compound, many countries (e.g., Italy, France, Spain,
Belgium, USA) so far failed using this approach, partly
due to limited capacity to implement similar measures.
Therefore, we believe an approach that can accommo-
date contract tracing imperfections, e.g., by reducing in-
fectiousness through the use of an antiviral compound,
is warranted.
We also tested the impact of outbreaks that are initi-
ated by multiple infectives, and the results are shown in
Additional File 1: Fig. S16. Final size and peak incidence
approximate the baseline scenario but the fade-out prob-
ability decreases. Nevertheless, the administration of an-
tivirals in combination with the other measures still
results in a higher fade-out probability compared to the
other tested scenarios, reducing the probability that an
outbreak will be major.
Conclusion
The ongoing epidemic of COVID-19 threatens to over-
whelm the health systems of many countries. Although
control measures such as isolation and quarantine are
important, their exclusive use may not be able to effi-
ciently contain an outbreak, requiring a prolonged lock-
down that could harm the economic system. In addition,
when a high proportion of infected individuals require
hospital care, the number of cases at peak should be
minimized as much as possible to avoid regional health
care infrastructure becoming overwhelmed. In the
current study, we highlight the importance of testing
compared to monitoring, and we show the impact of an
antiviral compound that reduces the viral load and, con-
sequently, the infectiousness of infectives. For this simu-
lation study, we utilized the data on the control of the
viral load by remdesivir in a pathogen challenge experi-
ment. However, this study can be easily extended to
other antivirals, given the availability of viral load data
upon drug administration. Although the efficacy of ad-
ministering an antiviral compound, in addition to isola-
tion and quarantine, depends on the effectiveness of the
respective drug, it is plausible that drugs that interfere
with the infection life cycle show a comparable impact
on the viral load. We demonstrate that the implementa-
tion of such a compound together with quarantine leads
to a substantial reduction of the final size and the peak
incidence. In addition, the number of outbreaks that are
most challenging to contain decreases when the antiviral
is administered to diagnosed and traced individuals. The
same result holds when the basic reproduction number
is set to an equal value for symptomatic and asymptom-
atic individuals (Additional File 1: Fig. S11) and when
the proportion of asymptomatic and diagnosed individ-
uals vary among the population (Additional File 1: Fig.
S3, Fig. S4, Fig. S5, Fig. S14, and Fig. S15). Therefore,
the administration of an antiviral drug, together with
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isolation and quarantine, is expected to have a major im-
pact in the control of local COVID-19 outbreaks. Al-
though antiviral drugs are mostly evaluated in clinical
trials for their capacity to control the disease manifesta-
tions and alter the clinical outcome in individual pa-
tients, our study implies that antiviral drugs can be
implemented to alter the spread of a viral epidemic by
influencing the viral load and infectiousness of infectees
upon quarantine. Given the fact that antiviral treatment
should be given in the quarantine setting, the route of
administration in relation to the frequency and duration
of treatment and the safety of the compound in healthy
volunteers are critical for the success of such an inter-
vention. Although oral formulations are desirable, intra-
veneous application in a limited outbreak could prevent
hospitalizations and thus reduce the pressure on the
health care capacity as the antiviral treatment is initiated
earlier in the disease.
However, such a treatment falls in many countries
under the responsibility of a prescribing practitioner that
is typically not part of the track and contact trace team.
An important consideration is the use of contact tra-
cing in combination with an antiviral to reduce the bur-
den on nursing home facilities. Recent work shows that
despite lockdowns, SARS-CoV-2 continues to spread in
such facilities, resulting in a high number of deaths [29].
We believe that the implementation of frequent testing,
contact tracing in combination with pharmaceutical
intervention (with an antiviral) to treat individuals of a
nursing home facility early, could have an important im-
pact on the number of deaths in these facilities.
We remain hopeful for drugs to be identified, either
directly or indirectly targeting the virus, that can be used
as a treatment for the hospitalized patient population.
Yet, our work shows that such compounds have an add-
itional potential to mitigate the pandemic when imple-
mented in concert with quarantine and contact tracing.
Therefore, research aimed at the identification of new
drugs and drug formulations suitable for the prophylac-
tic use for different viral families with pandemic poten-
tial remains warranted.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12916-020-01636-4.
Additional file 1. Sensitivity Analysis.
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